Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vivus Poised To Enter Phase III With Obesity Candidate Qnexa

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm touts safety advantage of experimental phentermine/topiramate combination therapy.

You may also be interested in...



Vivus’ Qnexa Works “Surprisingly” Well In Diabetes

Obesity drug could double its market opportunity, analysts say.

Vivus’ Qnexa Works “Surprisingly” Well In Diabetes

Obesity drug could double its market opportunity, analysts say.

Arena’s Lorcaserin Can Continue To Bloom In Phase III Obesity Trial

Safety monitoring board review of echocardiographic data gives firm a green light to continue with pivotal trial.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS066227

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel